Accentus Signs Licence Agreement with Zimmer
This agreement will enable the use of Accentus Medical’s Agluna anti-infective technology on a potentially broad range of Zimmer products.
Under the terms of the agreement, Zimmer will acquire exclusive global rights to utilize Agluna for joint reconstruction and trauma products. In addition, the company will have an 18-month option to acquire additional exclusive rights for spinal devices, dental implants and sports medicine products.
As part of the agreement, there will be an initial period of further development of Agluna. Accentus and Zimmer will collaborate to secure regulatory approval for products treated with the Agluna technology in both the EU and US.
According to Accentus, Agluna is a novel, patented surface modification technology applied to medical devices manufactured from titanium and its various alloys. The goal of the technology is to reduce infection rates following surgical procedures. Medical device materials have been shown to be susceptible to rapid colonisation by bacteria, which then produce a plaque or biofilm as protection against the body’s defences.
Implants treated with Agluna technology have been shown to remain clear of such biofilm formation. In vitro testing has demonstrated that Agluna surface technology has bactericidal effects against bacteria known to cause post-operative, device-related infection, including drug-resistant strains, said Accentus.
Martin Pickford, senior vice-president of business development for Accentus Medical, said: “One of the most intransigent problems with orthopaedic implants is infection. It can be very difficult, costly and time consuming to treat these cases. The most effective approach is to ensure that infections do not occur in the first place.
“All of our data to-date demonstrates that treating orthopaedic implants with the Agluna process can contribute towards achieving this goal. If successful in the long term, Agluna will help significantly reduce the estimated $5 billion in annual costs associated with infections resulting from primary joint replacement.”
Will the agreement benefit the firms?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.